

ROBIN OligoMET Center

Monthly Research Update: March 2025

Publications

MARCH AT A GLANCE TOTALS	
Publications	7
Grants and contracts	
New awards	0
Submitted	2
Oral Presentations	3
Abstracts	0
Clinical trials	
TERPS	0
Awards/Honors	0

Please submit all monthly updates to Jadyne Stewart at jadynewstewart@som.umaryland.edu by second Wednesday of each month.

- Andrews JR, Kim Y, Horjeti E, Arafa A, Gunn H, De Bruycker A, Phillips R, Song D, Childs DS, Sartor OA, Orme JJ, Chaudhuri AA, **Tran P**, Kiess A, Sutera P, Mercier C, Ost P, Park SS, Lucien F. **PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts.** Clin Cancer Res. 2025 Mar 17;31(6):1142-1149. doi: 10.1158/1078-0432.CCR-24-3027. PMID: 39820657; PMCID: PMC11911805.
- Esenturk E, Sahli A, Haberland V, Ziuboniewicz A, Wirth C, Bova GS, Bristow RG, Brook MN, Brors B, Butler A, Cancel-Tassin G, Cheng KC, Cooper CS, Corcoran NM, Cussenot O, Eeles RA, Favero F, Gerhauser C, Gihawi A, Girma EG, Gnanapragasam VJ, Gruber AJ, Hamid A, Hayes VM, He HH, Hovens CM, **Imada EL**, Jakobsdottir GM, Jung CH, Khani F, Kote-Jarai Z, Lamy P, Leeman G, **Loda M**, Lutsik P, **Marchionni L**, Molania R, Papenfuss AT, Pellegrina D, Pope B, Queiroz LR, Rausch T, Reimand J, Robinson B, Schlomm T, Sørensen KD, Uhrig S, Weischenfeldt J, Xu Y, Yamaguchi TN, Zanettini C, Lynch AG, Wedge DC, Brewer DS, Woodcock DJ. **Causes of evolutionary divergence in prostate cancer.** ArXiv [Preprint]. 2025 Mar 17:arXiv:2503.13189v1. PMID: 40166741; PMCID: PMC11957227.
- Fanelli GN, Nuzzo PV, Pederzoli F, **Loda M**. **Deciphering Complexity: The Molecular Landscape of Castration-Resistant Prostate Cancer.** Surg Pathol Clin. 2025 Mar;18(1):25-39. doi: 10.1016/j.path.2024.10.003. Epub 2024 Nov 29. PMID: 39890307; PMCID: PMC11787547.
- Haffner MC, Morris MJ, Ding CC, Sayar E, Mehra R, Robinson B, True LD, Gleave M, Lotan TL, Aggarwal R, Huang J, **Loda M**, Nelson PS, Rubin MA, Beltran H. **Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies.** Clin Cancer Res. 2025 Feb 3;31(3):466-478. doi: 10.1158/1078-0432.CCR-24-2061. PMID: 39589343; PMCID: PMC11790385.
- Logan JA, Sadhu S, Hazlewood C, Denton M, Burke SE, Simone-Soule CA, Black C, Ciaverelli C, Stulb J, Nourzadeh H, Vinogradskiy Y, Leader A, Dicker AP, Choi W, **Simone NL**. **Bridging Gaps in Cancer Care: Utilizing Large Language Models for Accessible Dietary Recommendations.** Nutrients. 2025 Mar 28;17(7):1176. doi: 10.3390/nu17071176. PMID: 40218934; PMCID: PMC11990115.
- Mastrolonardo EV, Llerena P, De Ravin E, Nunes K, Kaki PC, Bridgham KM, Amin DR, Campbell DJ, Philips R, Koeneman SH, Cognetti DM, Luginbuhl AJ, **Simone NL**, Johnson JM, Curry JM. **Improved survival with elevated BMI following immune checkpoint inhibition across various solid tumor cancer types.** Cancer. 2025 Mar 15;131(6):e35799. doi: 10.1002/cncr.35799. PMID: 40069917; PMCID: PMC11897419.

ROBIN OligoMET Center

Monthly Research Update: March 2025

Publications

- Shah KD, Yeap BY, Lee H, Soetan ZO, Moteabbed M, Muise S, Cowan J, Remillard K, Silvia B, Mendenhall NP, Soffen E, **Mishra MV**, Kamran SC, Miyamoto DT, Paganetti H, Efstathiou JA, Chamseddine I. [Predictive model of acute rectal toxicity in prostate cancer treated with radiotherapy](#). JCO Clin Cancer Inform. 2025 Mar;9:e2400252. Epub 2025 Mar 19.

Grants and Contracts

Funded:

- None Reported

Submitted:

- **Erika Davies, PhD, PI/PD**, on a subaward with Red Hill Biopharma to NIH/NIAID BAA-75N93024R00020 for “Development of radiation/nuclear medical countermeasures and biodosimetry devices” (up to \$2,773,437).
- **Erika Davies, PhD, PI/PD**, to NIAID BAA-75N93024R00020 for “Development of radiation/nuclear medical countermeasures and biodosimetry devices” (\$6,198,998)

Oral Presentations

- **Phuoc T.**, Allegheny Health Network Cancer Institute Grand Rounds (March 11, 2025 – Pittsburgh, PA). “How I use risk stratification tools in localized prostate cancer: NRG oncology initiatives to improve precision medicine radiation management”.
- **Phuoc T.**, Siemens Healthineers DTI Friday Seminar (March 14, 2025 – Virtual). “NRG Oncology GU Novel Molecular and Digital Pathology Approaches for Risk Stratification for Newly Diagnosed Localized Prostate Cancer”.
- **Phuoc T.**, OncLive Bridging the Gaps Prostate Cancer Meeting (March 27, 2025 – Weehawken, NJ). “Applying Radiation for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)”.

Abstracts

- None reported

Clinical Trial Enrollment

- 0 patients were enrolled (37/122 total) on the **TERPS trial**.

Awards/Honors

- None reported

Please note that these examples are representative of productivity from the ROBIN OligoMET Center members and are not exclusively attributable to the U54 grant.